TrialClinical cancer research : an official journal of the American Association for Cancer Research2011

Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.

Naiyer A Rizvi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.